Zentalis Pharmaceuticals stock falls after public offering pricing and trades below recent highs

Published on 09/18/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zentalis Pharmaceuticals stock closed at USD 3.08 on September 17, 2026, down 0.65 percent on Nasdaq after pricing a 23 million share offering at USD 3.50. The shares now trade less than half below the 52-week high of USD 6.95 while the company advances late stage oncology trials.

ZNTL, US98943L1070, Illustration mit AI erstellt.

Zentalis Pharmaceuticals stock (ISIN US98943L1070) closed at USD 3.08 on Nasdaq on September 17, 2026, a decline of 0.65 percent from the previous close of USD 3.10, while post-market trading lifted the price to USD 3.12.Seeking Alpha notes that this move comes shortly after the company priced a large public share offering.

Stock reacts to share offering at USD 3.50

As Seeking Alpha reports, Zentalis Pharmaceuticals recently priced a 23 million share public offering at USD 3.50 per share, adding new equity capital but also diluting existing shareholders. The stock quote section on September 17, 2026 shows a regular session close at USD 3.08, 0.65 percent below the prior close of USD 3.10, and a post-market indication at USD 3.12, while the 52-week range stands between USD 1.21 and USD 6.95.Seeking Alpha For investors this means the offering price of USD 3.50 currently sits around 13.6 percent above the USD 3.08 close but roughly 49.6 percent below the 52-week high of USD 6.95.

According to Seeking Alpha, Zentalis carries a market capitalization of about USD 293.48 million and had 94.67 million shares outstanding as of the latest trading data. The same overview lists a trading volume of 1,090,673 shares for the September 17, 2026 session and a short interest of 5.27 percent, highlighting that the name remains actively traded and that a non-trivial portion of the free float is held by short sellers.

Late stage oncology pipeline and financial profile

The San Diego based biopharmaceutical company Zentalis Pharmaceuticals, Inc. is a clinical-stage oncology developer focusing on small molecule therapeutics for various cancers in the United States.Seeking Alpha Its lead asset azenosertib is in a Phase 3 clinical trial for ovarian cancer and other tumor types, and the company also runs early stage studies such as ZN-c3-001 in solid tumors and the Phase 1/2 MAMMOTH trial in PARP inhibitor resistant ovarian cancer.Seeking Alpha For retail investors, this late stage pipeline means that the equity story hinges on future pivotal data, which according to recent analysis is expected in the first half of 2027 for azenosertib in platinum resistant ovarian cancer.Seeking Alpha

While detailed quarterly revenue and earnings figures are not broken out in the accessible sections of the recent week-filtered sources, the valuation and capital structure metrics give a picture of the current fundamentals. The company shows an enterprise value of about USD 156.56 million against cash of USD 174.61 million and total debt of USD 37.69 million, implying a net cash position.Seeking Alpha In addition, the revenue growth metric presented as revenue year on year of minus 33.76 percent underlines that reported top line has contracted compared with the prior period,Seeking Alpha a factor that adds to the market skepticism despite the significant cash runway.

Analyst stance, risk profile and momentum

On the rating side, the same data overview shows that Wall Street analysts currently classify Zentalis as a Buy, while the quantitative model assigns a Hold and Seeking Alpha analysts do not carry an active rating.Seeking Alpha Factor grades give the stock an A minus for valuation and an A for momentum, but only a D minus for profitability and a C for revisions, reflecting both the appeal of the current price level and the still weak earnings profile.

Risk metrics in the same source underline the volatility inherent in Zentalis Pharmaceuticals stock. The 24 month beta stands at 3.41, meaning that the shares have historically moved more than three times as much as the broader market, and short interest reaches 5.27 percent of the float with about 4.99 million shares short and days to cover at 5.13.Seeking Alpha For investors this combination means that any future clinical update or financing decision can trigger pronounced moves in both directions.

The momentum data over different horizons support this picture. Over the past one year, Zentalis Pharmaceuticals stock has gained about 118.31 percent compared with 15.72 percent for the S&P 500, and over nine months it is up 124.64 percent.Seeking Alpha However, the three month performance shows a decline of 11.93 percent, indicating that after the strong recovery from the 52-week low of USD 1.21 the stock has recently consolidated and given back part of its gains.

Zentalis stock level and trading context

Per the latest Nasdaq referenced data on September 17, 2026, Zentalis Pharmaceuticals stock traded in a day range between USD 3.02 and USD 3.22 and closed at USD 3.08, with a previous close at USD 3.10 and a post-market indication at USD 3.12.Seeking Alpha Relative to the 52-week low of USD 1.21, this price represents an increase of about 154.6 percent, while the distance to the 52-week high of USD 6.95 is about 55.7 percent, situating the shares roughly in the middle of their one year range.